Abstract
Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 425-429 |
| Number of pages | 5 |
| Journal | Bone Marrow Transplantation |
| Volume | 6 |
| Issue number | 6 |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission. / Lenarsky, C.; Weinberg, K.; Petersen, J.; Nolta, Jan; Brooks, J.; Annett, G.; Kohn, D.; Parkman, R.
In: Bone Marrow Transplantation, Vol. 6, No. 6, 1990, p. 425-429.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission
AU - Lenarsky, C.
AU - Weinberg, K.
AU - Petersen, J.
AU - Nolta, Jan
AU - Brooks, J.
AU - Annett, G.
AU - Kohn, D.
AU - Parkman, R.
PY - 1990
Y1 - 1990
N2 - Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.
AB - Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.
UR - http://www.scopus.com/inward/record.url?scp=0025688660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025688660&partnerID=8YFLogxK
M3 - Article
VL - 6
SP - 425
EP - 429
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -